VIP and histamine H2 receptor activity in human fetal gastric glands.
Vasoactive intestinal peptide (VIP, EC50 = 6.4 X 10(-10)M) and histamine (EC50 = 3 X 10(-6)M) activated the cyclic AMP generating system in gastric glands isolated from two human fetuses at 23 weeks gestation. Histamine antagonism by the H2 receptor blockers cimetidine (Ki = 0.35 X 10(-6)M) and ranitidine (ki = 0.51 X 10(-7)M) clearly characterized the histaminic activation as being of the H2 type. It is suggested that these two vasoactive hormones may operate as neurocrine/paracrine regulators of the differentiation and/or function of the human gastric mucosa in utero.
D002927:Cimetidine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D005333:Fetus; D005753:Gastric Mucosa / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D011247:Pregnancy; D011899:Ranitidine / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011968:Receptors, Histamine / Q000378:metabolism*; D011970:Receptors, Histamine H2 / Q000378:metabolism*; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism* / Q000494:pharmacology
D011956:Receptors, Cell Surface; D011968:Receptors, Histamine; D011970:Receptors, Histamine H2; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide; D002927:Cimetidine; D006632:Histamine; D011899:Ranitidine; D000242:Cyclic AMP